Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DKSH Business Unit Healthcare and Actelion's affiliate Actelion Pharmaceuticals Singapore have entered into collaboration to support the business growth in Asia.
Subscribe to our email newsletter
Under the deal, DKSH will be responsible for providing regulatory, distribution and logistics services for Actelion in Hong Kong, Malaysia and Singapore.
Initially, the deal covers Tracleer, a prescription medicine indicated to treat patients with certain types of pulmonary arterial hypertension (PAH).
Actelion Pharmaceuticals Australia Asia Pacific Region vice-president Simon Eade said: "In DKSH we found a reliable partner to grow our business in the fast growing Asian market.
"We are convinced of DKSH’s commitment to the highest international quality and compliance standards across all operations.
"The convenience of having one regional point-of-contact with strong local regulatory expertise should simplify collaboration across multiple markets."
The collaboration, which is pending product registration in Hong Kong, Malaysia and Singapore, may also be extended to include Opsumit (macitentan), an orally available endothelin receptor antagonist (ERA).
Since November 2013, opsumit has been available in the US and is currently undergoing regulatory review in various other markets worldwide.